These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12679354)

  • 1. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy.
    He Q; Engelson ES; Albu JB; Heymsfield SB; Kotler DP
    J Appl Physiol (1985); 2003 May; 94(5):2051-7. PubMed ID: 12679354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.
    Viganò A; Mora S; Manzoni P; Schneider L; Beretta S; Molinaro M; di Natale B; Brambilla P
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4075-80. PubMed ID: 15840750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy.
    Johnson JA; Albu JB; Engelson ES; Fried SK; Inada Y; Ionescu G; Kotler DP
    Am J Physiol Endocrinol Metab; 2004 Feb; 286(2):E261-71. PubMed ID: 14532165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy.
    Bickel M; Zangos S; Jacobi V; Lutz T; Knecht G; Goebel F; Staszewski S; Klauke S
    HIV Med; 2006 Sep; 7(6):397-403. PubMed ID: 16903985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
    Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.
    Engelson ES; Glesby MJ; Mendez D; Albu JB; Wang J; Heymsfield SB; Kotler DP
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):379-91. PubMed ID: 12138344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating sex hormones and gene expression of subcutaneous adipose tissue oestrogen and alpha-adrenergic receptors in HIV-lipodystrophy: implications for fat distribution.
    Andersen O; Pedersen SB; Svenstrup B; Hansen BR; Paulsen SK; Rathje GS; Richelsen B; Nielsen JO; Madsbad S; Iversen J; Haugaard SB
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):250-8. PubMed ID: 17524033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.
    Benedini S; Terruzzi I; Lazzarin A; Luzi L
    BioDrugs; 2008; 22(2):101-12. PubMed ID: 18345707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
    Andersen O; Haugaard SB; Flyvbjerg A; Andersen UB; Ørskov H; Madsbad S; Nielsen JO; Iversen J
    Eur J Clin Invest; 2004 Aug; 34(8):561-8. PubMed ID: 15305891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic therapy for HIV-associated lipodystrophy.
    Benavides S; Nahata MC
    Ann Pharmacother; 2004 Mar; 38(3):448-57. PubMed ID: 14755064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy.
    Luzi L; Perseghin G; Tambussi G; Meneghini E; Scifo P; Pagliato E; Del Maschio A; Testolin G; Lazzarin A
    Am J Physiol Endocrinol Metab; 2003 Feb; 284(2):E274-80. PubMed ID: 12388139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
    Hammond E; McKinnon E; Nolan D
    Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.
    Bickel M; Zangos S; Lutz T; Eisen J; Knecht G; Goebel FD; Crespi CM; Jacobi V; Staszewski S; Klauke S
    Scand J Infect Dis; 2008; 40(1):36-9. PubMed ID: 17852925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study.
    Lo JC; Mulligan K; Noor MA; Lee GA; Schwarz JM; Grunfeld C; Schambelan M
    Clin Infect Dis; 2004 Sep; 39(5):732-5. PubMed ID: 15356790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.
    Macallan DC; Baldwin C; Mandalia S; Pandol-Kaljevic V; Higgins N; Grundy A; Moyle GJ
    HIV Clin Trials; 2008; 9(4):254-68. PubMed ID: 18753120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantification of HIV-1-associated lipodystrophy.
    Bickel M; Eisen J; Stephan C; Crespi CM; Lutz T; Klauke S; Vogl TJ; Jacobi V; Yang OO; Staszewski S; Zangos S
    HIV Med; 2007 Oct; 8(7):413-9. PubMed ID: 17760732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.
    Hu M; Tomlinson B
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1143-50. PubMed ID: 20872317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
    Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
    Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.